At the news
? BULLISHIMPACT 8/10 8-K filed Apr 23, 2026 at 07:11 ET
West Pharmaceutical Services reported strong Q1 2026 results with revenue of $844.9M (+21.0% YoY) and adjusted EPS of $2.13 (+46.9% YoY), significantly beating consensus. The company raised its full-year 2026 revenue guidance to $3.295B-$3.350B and adjusted EPS guidance to $8.40-$8.75, driven by strong organic growth in high-value products and GLP-1 demand.
- Q1 2026 revenue: $844.9M, +21.0% YoY (+15.3% organic)
- Q1 2026 adjusted EPS: $2.13, +46.9% YoY
- Raised full-year 2026 revenue guidance to $3.295B-$3.350B (from $3.215B-$3.275B)
- Raised full-year 2026 adjusted EPS guidance to $8.40-$8.75 (from $7.85-$8.20)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access